The Orphanet Rare Disease Ontology (ORDO) and the Human Phenotype Ontology (HPO) are considered the most relevant ontologies to be
used in the rare disease research and, more specifically, in RD - Connect.
The goal of IRDiRC is to team up researchers and funding organizations across the world that are strongly
involved in rare diseases research in order to achieve two main and ambitious objectives: deliver 200 new therapies for rare diseases and means to diagnose most rare diseases by the year 2020.
Capitalizing on the momentum of progress made
in rare diseases research over the past six years, the International Rare Diseases Research Consortium (IRDiRC) devised a new set of global rare disease goals for the upcoming decade.
IRDiRC invests effort to disseminate the Policies and Guidelines as best practices in international rare diseases research, assesses their impact, and updates them, as needed, to reflect changing needs and
relevancy in rare diseases research.
Funding organizations (i.e., funding bodies, groups of funders (for small funders), companies) investing more than 10 million USD over 5 years in rare disease research
In general, the growing participation of CNAG -
CRG in rare disease research projects is clear in terms of samples sequenced; while during the period 2014/2015 the total number of processed samples related to rare diseases was of 523 in the period 2016/2017 the number of these samples increased to more than 1600.